OncoGenex Regains Rights to Custirsen from Teva

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. CRWV
2. NVDA
3. SPY
4. BAC
5. BLK
6. AA
7. RKLB
8. RXRX
9. NOW
10. CAT

Go back to OncoGenex Regains Rights to Custirsen from Teva

OncoGenex Pharma (OGXI) Will Regain Custirsen Rights from Teva (TEVA)

April 27, 2015 6:34 AM EDT

OncoGenex Pharma (NASDAQ: OGXI) announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. (NYSE: TEVA) under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva.

"OncoGenex is excited to move forward with the clinical investigation of custirsen in patients with advanced cancers who desperately need new treatment... More